Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Dexcom (DXCM) Gross Margin (2016 - 2026)

Dexcom has reported Gross Margin over the past 17 years, most recently at 62.95% for Q1 2026.

  • Quarterly Gross Margin rose 610.0% to 62.95% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 61.5% through Mar 2026, up 207.0% year-over-year, with the annual reading at 60.1% for FY2025, 36.0% down from the prior year.
  • Gross Margin was 62.95% for Q1 2026 at Dexcom, roughly flat from 62.93% in the prior quarter.
  • Over five years, Gross Margin peaked at 66.4% in Q4 2022 and troughed at 56.85% in Q1 2025.
  • The 5-year median for Gross Margin is 62.71% (2023), against an average of 62.1%.
  • Year-over-year, Gross Margin plummeted -552bps in 2022 and then skyrocketed 610bps in 2026.
  • A 5-year view of Gross Margin shows it stood at 66.4% in 2022, then decreased by -4bps to 63.47% in 2023, then dropped by -7bps to 58.9% in 2024, then rose by 7bps to 62.93% in 2025, then rose by 0bps to 62.95% in 2026.
  • Per Business Quant, the three most recent readings for DXCM's Gross Margin are 62.95% (Q1 2026), 62.93% (Q4 2025), and 60.48% (Q3 2025).